Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study

Background and Purposes— This study was designed to derive and validate a score to predict early ischemic events and major bleedings after an acute ischemic stroke in patients with atrial fibrillation. Methods— The derivation cohort consisted of 854 patients with acute ischemic stroke and atrial fibrillation included in prospective series between January 2012 and March 2014. Older age (hazard ratio 1.06 for each additional year; 95% confidence interval, 1.00–1.11) and severe atrial enlargement (hazard ratio, 2.05; 95% confidence interval, 1.08–2.87) were predictors for ischemic outcome events (stroke, transient ischemic attack, and systemic embolism) at 90 days from acute stroke. Small lesions (⩽1.5 cm) were inversely correlated with both major bleeding (hazard ratio, 0.39; P=0.03) and ischemic outcome events (hazard ratio, 0.55; 95% confidence interval, 0.30–1.00). We assigned to age ≥80 years 2 points and between 70 and 79 years 1 point; ischemic index lesion >1.5 cm, 1 point; severe atrial enlargement, 1 point (ALESSA score). A logistic regression with the receiver-operating characteristic graph procedure (C statistic) showed an area under the curve of 0.697 (0.632–0.763; P=0.0001) for ischemic outcome events and 0.585 (0.493–0.678; P=0.10) for major bleedings. Results— The validation cohort consisted of 994 patients included in prospective series between April 2014 and June 2016. Logistic regression with the receiver-operating characteristic graph procedure showed an area under the curve of 0.646 (0.529–0.763; P=0.009) for ischemic outcome events and 0.407 (0.275–0.540; P=0.14) for hemorrhagic outcome events. Conclusions— In acute stroke patients with atrial fibrillation, high ALESSA scores were associated with a high risk of ischemic events but not of major bleedings.

K. Furie | W. Ageno | M. Mancuso | S. Sacco | Monica Acciarresi | V. Caso | L. Csiba | S. Monaco | A. Carolei | T. Tatlisumak | A. Padovani | K. Lees | A. Abdul-Rahim | J. Putaala | M. Zedde | G. Tsivgoulis | A. Pezzini | F. Bandini | G. Agnelli | Antonio Procopio | K. Barlinn | D. Toni | D. Consoli | U. Scoditti | P. Michel | Alberto Rigatelli | S. Yaghi | D. Imberti | S. Sohn | M. Paciaroni | F. Corea | M. Venti | D. Deleu | P. Bovi | Christina M Rueckert | J. Kepplinger | M. Cappellari | M. Acampa | N. Mumoli | G. Bono | F. Guideri | N. Akhtar | M. Del Sette | P. Tadi | S. Marcheselli | G. Gialdini | G. Orlandi | R. Tassi | N. Giannini | T. Karapanayiotides | O. Kargiotis | G. Ntaios | G. Martini | L. Szabó | C. Becattini | L. Cimini | L. Masotti | G. Lorenzini | P. Vanacker | C. Tiseo | A. Chiti | G. Melikyan | A. Alberti | V. Vannucchi | G. Colombo | M. Chondrogianni | A. Ciccone | U. Bodechtel | J. Gerber | A. Baldi | G. Silvestrelli | E. Giorli | K. Vadikolias | B. Doronin | Lars-Peder Pallesen | L. Denti | M. Carletti | Efstathia Karagkiozi | L. Poli | M. Giuntini | M. Bellesini | T. Tassinari | A. Pieroni | Faisal Ibrahim | Cataldo D’Amore | S. D’Anna | F. Letteri | M. G. Mosconi | E. Lotti | F. Galati | C. Liantinioti | Y. Flomin | M. Maccarrone | V. Volodina | N. Falocci | L. Tomppo | George Athanasakis | K. Makaritsis | M. L. De Lodovici | M. M. Baronello | D. Zabzuni | V. Gourbali | Marta Bellesini | L. A. Cimini | Vanessa Gourbali | Kostantinos Makaritsis | Azmil H. Abdul-Rahim | C. Rueckert | M. D. De Lodovici

[1]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[2]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[3]  Gerhard Schroth,et al.  NIHSS Score and Arteriographic Findings in Acute Ischemic Stroke , 2005, Stroke.

[4]  William Stewart,et al.  Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[5]  V. Caso,et al.  Clinical Benefit of Early Anticoagulation in Cardioembolic Stroke , 2008, Cerebrovascular Diseases.

[6]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[7]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[8]  J. Switzer,et al.  Predicting outcome of IV thrombolysis-treated ischemic stroke patients: The DRAGON score , 2012, Neurology.

[9]  W. Ageno,et al.  Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study , 2016, Journal of Neurology.

[10]  W. Ageno,et al.  Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing The RAF Study , 2015, Stroke.

[11]  W. Ageno,et al.  Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation , 2016, Thrombosis and Haemostasis.

[12]  K. Furie,et al.  Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes , 2018, Journal of the American Heart Association.